MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-04-2026
SCYNEXIS EPS Ratio 2011-2026 | SCYX
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio SCYNEXIS
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.17 | -0.44 | 1.4 | -1.47 | -1.25 | - | -0.96 | -0.28 | -0.94 | -1.58 | -2.68 | -1.04 | -139 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.4 | -139 | -12.4 |
Quarterly EPS Ratio SCYNEXIS
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.17 | -0.14 | -0.11 | - | -0.06 | -0.3 | 0.01 | - | -0.04 | 2.56 | -0.71 | - | -0.62 | -0.31 | -0.17 | - | -0.02 | 0.06 | -0.18 | - | 0.09 | -0.64 | -0.72 | - | -1.43 | -1.58 | -0.46 | - | 0.01 | -0.23 | -0.12 | - | -0.31 | -0.16 | -0.19 | -0.02 | -0.48 | -0.56 | -0.52 | -0.55 | -0.6 | -0.78 | -0.75 | - | -0.45 | 0.38 | -3.65 | - | -11.8 | -8.05 | -6.16 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.56 | -11.8 | -0.974 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Drug manufacturers industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-0.34 | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-0.18 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.61 | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
-4.74 | $ 19.21 | -3.37 % | $ 123 M | USA |
 |
Canopy Growth Corporation
CGC
|
-5.56 | $ 1.0 | 2.63 % | $ 108 M |  Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
-0.51 | - | - | $ 2.06 B |  France |
 |
Aurora Cannabis
ACB
|
-4.1 | $ 3.44 | 2.69 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
-5.76 | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
-6.71 | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-0.84 | - | - | $ 142 M | USA |
 |
China Pharma Holdings
CPHI
|
-0.74 | $ 0.63 | -1.56 % | $ 2.7 M |  China |
 |
Athenex
ATNX
|
-15.8 | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.76 | - | -39.89 % | $ 27.7 M | USA |
 |
DURECT Corporation
DRRX
|
-1.05 | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
-14.8 | $ 8.23 | -1.79 % | $ 421 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-9.66 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Evoke Pharma
EVOK
|
-2.33 | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
-0.89 | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-0.14 | $ 3.17 | 2.26 % | $ 44.6 M | USA |
 |
Endo International plc
ENDP
|
-10.4 | - | - | $ 28.9 M |  Irlanda |
 |
Bausch Health Companies
BHC
|
-1.62 | $ 5.35 | -4.12 % | $ 1.95 B | Canada |
 |
Harrow Health
HROW
|
-0.14 | $ 35.31 | -0.34 % | $ 1.3 B | USA |
 |
Jupiter Wellness
JUPW
|
-17 | - | - | $ 33.6 M | USA |
 |
Evolus
EOLS
|
-0.8 | $ 4.03 | -6.5 % | $ 260 M | USA |
 |
Lannett Company
LCI
|
-5.74 | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-4.24 | - | - | $ 193 M | Canada |
 |
OptiNose
OPTN
|
-0.32 | - | - | $ 1.08 B | USA |
 |
Organogenesis Holdings
ORGO
|
-0.01 | $ 2.24 | -3.03 % | $ 295 M | USA |
 |
Pacira BioSciences
PCRX
|
-2.15 | $ 22.7 | -0.39 % | $ 1.05 B | USA |
 |
PetIQ
PETQ
|
0.07 | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
-2.06 | - | -27.8 % | $ 2.56 M | USA |
 |
Perrigo Company plc
PRGO
|
-10.3 | $ 10.85 | -1.36 % | $ 1.5 B | USA |
 |
ProPhase Labs
PRPH
|
1.17 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-1.49 | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
-1.45 | $ 6.99 | -1.55 % | $ 276 M | USA |
 |
Recro Pharma
REPH
|
-0.14 | - | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
-0.15 | $ 0.96 | 2.54 % | $ 34.5 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-2.79 | $ 2.37 | -2.47 % | $ 2.94 M | USA |
 |
Solid Biosciences
SLDB
|
-1.99 | $ 7.49 | 1.49 % | $ 655 M | USA |
 |
Viatris
VTRS
|
0.05 | $ 13.44 | -1.39 % | $ 16.1 B | USA |
 |
cbdMD
YCBD
|
-1.79 | $ 0.73 | 2.37 % | $ 3.15 M | USA |
 |
Zomedica Corp.
ZOM
|
-0.08 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-0.82 | - | - | $ 55.5 M | USA |
 |
Tricida
TCDA
|
-3.44 | - | - | $ 3.25 M | USA |
 |
OrganiGram Holdings
OGI
|
-0.51 | $ 1.38 | 2.99 % | $ 402 M | Canada |
 |
TherapeuticsMD
TXMD
|
-0.05 | $ 2.0 | - | $ 23.1 M | USA |
 |
Sundial Growers
SNDL
|
-1.1 | $ 1.36 | 2.26 % | $ 3.37 M | Canada |
 |
Tilray
TLRY
|
-2.35 | $ 6.55 | 6.68 % | $ 4.05 B | Canada |